Association of single nucleotide polymorphisms in the polymeric immunoglobulin receptor gene with immunoglobulin A nephropathy
(IgAN) in Japanese patients.
Immunoglobulin A nephropathy
(IgAN) is the most prevalent primary chronic glomerular disease worldwide.[sup] In China, IgAN accounts for 33.19% of total renal biopsy diagnoses and 45.26% of primary glomerular diseases.[sup] Approximately 10% of IgAN patients demonstrate an accelerated loss of renal function and 30–40% slowly progress to renal failure;[sup] however, proteinuria control can improve the prognoses for IgAN.[sup] Pathogenesis and progression of IgAN are related to many factors, including heredity, inflammation, renin-angiotensin system activity, extracellular matrix metabolism, and abnormal blood coagulation.[sup], An effective delay or blockade of IgAN progression may require multiple treatments.
Association of a single nucleotide polymorphism in the immunoglobulin mu-binding protein 2 gene with immunoglobulin A nephropathy
Phase 3 clinical programs are in progress for OMS721 in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), in immunoglobulin A nephropathy
, and in atypical hemolytic uremic syndrome.
Omeros announced the formation of an independent Academic Leadership Committee to support its Phase 3 clinical program for OMS721 in immunoglobulin A nephropathy
. The committee will provide clinical guidance to Omeros as it advances its ongoing IgA nephropathy Phase 3 clinical trial ARTEMIS-IGAN.
Phase 3 clinical programmes are in progress for OMS721 in atypical hemolytic uremic syndrome, in immunoglobulin A nephropathy
and in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).